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ImmunotherapyAutoimmune neuropathies occur when immunologic tolerance to myelin or axonal antigens is lost. Even though
the triggering factors and the underling immunopathology have not been fully elucidated in all neuropathy sub-
sets, immunological studies on the patients' nerves, transfer experiments with the patients' serum or intraneural
injections, andmolecularﬁngerprinting on circulating autoantibodies or autoreactive T cells, indicate that cellular
and humoral factors, either independently or in concert with each other, play a fundamental role in their cause.
The review is focused on the main subtypes of autoimmune neuropathies, mainly the Guillain–Barré syn-
drome(s), the Chronic Inﬂammatory Demyelinating Polyneuropathy (CIDP), the Multifocal Motor Neuropathy
(MMN), and the IgM anti-MAG-antibodymediated neuropathy. It addresses the factors associatedwith breaking
tolerance, examines the T cell activation process including co-stimulatory molecules and key cytokines, and dis-
cusses the role of antibodies against peripheral nerve glycolipids or glycoproteins. Special attention is given to the
newly identiﬁed proteins in the nodal, paranodal and juxtaparanodal regions as potential antigenic targets that
could best explain conduction failure and rapid recovery. New biological agents against T cells, cytokines, B
cells, transmigration and transduction molecules involved in their immunopathologic network, are discussed
as future therapeutic options in difﬁcult cases. This article is part of a Special Issue entitled: Neuromuscular
Diseases: Pathology and Molecular Pathogenesis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Autoimmune Peripheral Neuropathies (APN) develop when immu-
nologic tolerance to key antigenic sites on the myelin, axon, nodes of
Ranvier or ganglionic neurons is lost [1,2]. Current evidence supports
the notion that in APN the autoimmunity is mediated by antibodies di-
rected againstmyelin antigens, alongwith autoreactive T cells andmac-
rophages that invade myelin sheath, axonal membranes or the nodes of
Ranvier. In some APN the triggering factors have been identiﬁed and
progress has been made in understanding the key players involved in
the immunopathogenic network; in several others however, the exact
immunopathologic mechanisms remain still unclear, but autoimmunity
is suspected based on the presence of antibodies, sensitized T cell inﬁl-
trates in the peripheral nerves, response to immunotherapies or coexis-
tence with another autoimmune disease or viral infections. The APN are
clinically important because they respond to immunotherapies based
on controlled studies, or have the potential to respond if more effectiveuscular Diseases: Pathology and
pt. of Pathophysiology, National
thens, 11527 Greece. Tel.: +30agents are used. The review addresses the autoimmune pathways in-
volved in the pathogenesis of themost common autoimmune neuropa-
thies and highlights the rationale for target-speciﬁc immunotherapies.1.1. Main clinicopathologic features of common APN
The common autoimmune neuropathies include: 1) Acute Inﬂam-
matory Polyneuropathy [the Guillain–Barré Syndrome(s)]; 2) Chronic
inﬂammatory demyelinating polyneuropathy (CIDP) and its variants;
3) Multifocal motor neuropathy with conduction block; and 4)
Polyneuropathies associated with IgM monoclonal gammopathies and
anti-MAG antibodies [1,2]. Other less common immune-mediated neu-
ropathies that will not be addressed here because their pathogenesis is
less clear include: the paraneoplastic neuropathies associatedwith anti-
Hu antibodies, vasculitic neuropathies due to isolated peripheral nerve
vasculitis, certain diabetic demyelinating or inﬂammatory neuropathies
where an immune component appears prominent, and the neuropa-
thies associated with systemic autoimmune disorders.
As discussed below and elaborated previously [1,2], in some APN,
like certain GBS variants and the anti-MAG neuropathy, themain target
antigens have been identiﬁed and the antibodies against them are well
characterized; in the most common neuropathies however, like the de-
myelinating variant of GBS and the CIDP, the target antigens remain still
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immunopathology.
The Guillain–Barré syndrome(s) (GBS) presents with an acute
(within 1–3 weeks) ascending motor weakness, areﬂexia, and mild to
moderate sensory abnormalities [1–5]. The neuropathy is inﬂammatory,
with perivascular and endoneurial lymphoid cell inﬁltrates throughout
the nerves, roots or plexuses, and demyelinatingwith signs of segmental
demyelination induced by complement-ﬁxing antibodies and macro-
phages as the ﬁnal effector cells. GBS represents several syndromes –
or variants – according to whether the main clinicopathologic involve-
ment is centered onmotor or sensory nerve ﬁbers andwhether it affects
predominantly the myelin or the axon [1–4]. Accordingly, the GBS syn-
dromes comprise the following subtypes: i) the acute inﬂammatory de-
myelinating polyneuropathy (AIDP), where the main target appears to
be the myelin and accounts for the majority of GBS patients; ii) the
acute, motor axonal neuropathy (AMAN), where the primary pathology
is in the axon, either due tomassive acute demyelination and inﬂamma-
tion, as occurs in experimental allergic neuritis when animals are im-
munized with a high dose of myelin antigens [1,2,6], or due to a
primary attack on the axons and the nodes of Ranviermediated bymac-
rophages and antibodies. A number of these cases have high GM1 anti-
bodies and, as discussed later, report an antecedent infection with
Campylobacter jejuni [2,3,7]; iii) the acute motor–sensory axonal neurop-
athy (AMSAN), which is like AMAN but with concurrent involvement of
the sensory axons; iv) the Miller-Fisher syndrome, characterized by
ophthalmoplegia, gait ataxia, and areﬂexia [1–5], a rather distinct vari-
ant because of theunique clinical phenotype and the presence of IgG an-
tibodies against GQ1b ganglioside [1–4,7,8]; vi) the sensory ataxic GBS,
probably due to involvement of dorsal roots and ganglionic neurons;
some of these patients have also IgG antibodies to GQ1b or GD1b gangli-
oside and may be forming a continuumwith Miller-Fisher syndrome or
share autoantibodies with the same sialic groups [1,2,8,9]; and vii) the
acute pandysautonomic neuropathywhere the target antigen is probably
in the sympathetic ganglionic neurons [1,2].
1.1.1. Chronic inﬂammatory demyelinating polyneuropathy (CIDP)
This is the most common APN with prevalence as high as 9/100,000
[2,10,11], and the most gratifying neuropathy because it is treatable in
the majority of the cases [2]. CIDP is viewed as the chronic counterpart
of GBS [1,2] because it shareswithGBS certain clinical, electrophysiolog-
ic, histologic, laboratory and autoimmune features. It differs from GBS
predominantly by its tempo, mode of evolution, prognosis, and respon-
siveness to steroids or immunosuppressants [1,2,10,12,16]. On electro-
physiological grounds, CIDP demonstrates features of demyelination in
motor and sensory ﬁbers with slow conduction velocity, dispersion of
the compound muscle action potentials, conduction block in at least
one nerve, prolonged distal motor or sensory latencies and prolonged
Fwave latencies. On histological grounds, there is evidence of demyelin-
ation associated with macrophages, complement and activated T cells
[10,12–16]. The demyelination in CIDP is also multifocal, like the one
seen in GBS, affecting spinal roots, plexuses and proximal nerve trunks
[13–15], accounting for the variable distribution of symptoms and
signs, which are clinically expressed as CIDP variants [10]. The most
notable CIDP variables are the asymmetric, unifocal or multifocal motor–
sensory form (the Lewis-Sumner syndrome); the pure motor form; the
pure sensory form; the sensory ataxic form; and the pure distal [1,2,10,
12,16].
1.1.2. Multifocal motor neuropathy (MMN) with conduction block
MMN has distinct clinical and electrophysiologic criteria, namely,
weakness in the distribution of individual motor nerves and multifocal
conduction block limited to motor but sparing the sensory nerves [1,2,
17]. In contrast to CIDP, where conduction in the sensory nerves is
also affected and sensory responses may not be elicited, in MMN the
sensory conduction remains normal across the nerve segments that
have the motor block. The reasons for such a selective motorinvolvement remain unclear. Differences in the myelin composition,
leading to distinct antigenic speciﬁcities betweenmotor and sensory ﬁ-
bers, have been implicatedmainly because the ceramide content within
the gangliosides differs between sensory and motor ﬁbers [1,2,8]; the
reasons however may be more complex and relate to the uniqueness
of the targeted antigens not within the compact myelin but rather in
the nodal regions and axonal membrane at the nodes of Ranvier. Up
to 50% of MMN patients have high IgM anti-GM1 antibody titers, but
the pathogenic role of these antibodies remains unclear [1,2,17], in
spite of recent evidence that GM1 antibodies ﬁx complement and may
induce a complement-mediated nodal dysfunction that reverses after
IVIg therapy [18]. The suggestion that GM1 antibodies bind to GM1
and interfere with saltatory conduction, has not been conﬁrmed and
GM1-binding sites have not been co-localized with voltage-gated sodi-
um channels at the nodes of Ranvier. Even though the immunopatholo-
gy remains uncertain, MMN patients respond remarkably well to
immunotherapy with IVIg.
1.1.3. IgM MGUS polyneuropathies with anti-MAG or ganglioside antibodies
The majority of these patients present with a chronic, slowly pro-
gressive, large-ﬁber, sensory polyneuropathy of insidious onset, mani-
fested as sensory ataxia [1,2,19–21]. Other times, it presents as
sensorimotor polyneuropathy with mixed features of demyelination
and axonal loss. Conduction velocity is slow with a rather characteristic
prolonged distal motor and sensory latencies consistent with distal de-
myelination. The serum protein electrophoresis shows a monoclonal
IgM spike that recognizes antigenic components on the compact mye-
lin, most of the times the Myelin Associated Glycoprotein (MAG) [21],
as discussed later. Sural nerve biopsy demonstrates diminished number
of myelinated axons with a characteristic splitting of the outer myelin
lamellae, linked to deposition of IgM that recognizes MAG in the same
area of the split myelin [1,2,21].
1.2. Immunopathogenesis
In general, complement-ﬁxing antibodies, macrophages and T cells
are themain effectormechanisms in all APN. In vitro and in vivo studies,
including immunization of animals withmyelin proteins, disease trans-
fer experiments with the patients' serum or with intraneural injections,
immunocytochemical studies on the patients' nerves, and T cell proﬁl-
ing studies in the peripheral blood, have provided evidence that both
cellular and humoral factors, either independently or in concert with
each other, play a central role in their pathogenesis [1,2].
1.3. GBS
1.3.1. Cellular factors
In autopsy cases of GBS patients, perivascular and endoneurial in-
ﬂammatory inﬁltrates are observed throughout the nerves, roots or
plexuses along with segmental demyelination mediated by macro-
phages, especially in areas with lymphoid inﬁltrates [1–4]. The macro-
phages break through the basement membrane of healthy Schwann
cells andmake direct contact with the outermostmyelin lamellae, lead-
ing to destruction of the superﬁcial myelin sheath [1–5]. Cytokines and
chemokines released by the activated T cells or complement activation,
may increase capillary permeability and facilitate transmigration of ad-
ditional macrophages or T cells. Increased levels of IL-2 and soluble IL-2
receptors are also noted in the serum during the acute phase of GBS
suggesting ongoing T-cell activation [3]. Further, lymphocytes from
GBS patients exert myelinotoxic activity when applied to cultures of
myelinated axons [1,2]. The involvement of a T cell-mediated process
in GBShas been strengthened byobservations in the experimental aller-
gic neuritis (EAN)model induced in animals immunizedwith thewhole
human nerve or with various peripheral nerve myelin proteins, such as
Po, P2, or galactocerebroside. These animals develop EANwith segmen-
tal demyelination and mononuclear cell inﬁltrates consisting of
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can passively transfer the disease to healthy animals [1–4].1.3.2. Humoral factors: the role of anti-ganglioside antibodies and molecular
mimicry
There is a stronger supporting evidence that circulating serum fac-
tors play a role in the pathogenesis of GBS. On clinical grounds, this is
based on the beneﬁcial effect of plasmapheresis that removes putative
pathogenic antibodies and other inﬂammatory mediators relevant to
demyelination and conduction block [1–5]; on laboratory grounds it is
based on the variety of autoantibodies detected in the patients' serum.
It has been known for years that serum from the acute phase of GBS
patients can demyelinate rodent dorsal root ganglionic extracts in a
complement-dependent manner. Further, GBS serum injected into rat
sciatic nerves can cause demyelination and conduction block [1–5]. Im-
munocytochemical studies on peripheral nerves fromGBSpatients have
shown deposits of IgG, IgM and membranolytic attack complex, imply-
ing complement-ﬁxing antibodies against myelinated ﬁbers [1–5]. Ad-
ditionally, complement-ﬁxing IgM antibodies against a peripheral
nerve glycolipid that contains carbohydrate epitopes and various sulfat-
ed or acidic glycosphingolipids, have been detected in the serum of GBS
patients [1–5,7–9].
The interest has been focused on gangliosides as the more likely an-
tigenic targets because they are abundant in the peripheral nerve and
can elicit an immune response because their signature sugar residues
bearing one or more sialic acid molecules (such as ganglioside GM1
that contains one sialic acid, GD1a with two, GT1a with three, or GQ1b
with four sialic acids), are exposed at the extracellular surface [1,2,7,
19]. Different ganglioside antibodies associated with speciﬁc GBS sub-
types appear pathogenic [1,2,8,9]; for example, immunization of rabbits
with GM1 or GD1b induces an acute neuropathy with histological fea-
tures of AMAN, while GQ1b or GD1a antibodies may cause conduction
block at themotor nerve terminals in amouse phrenic nerve preparation
[1–3,8,9]. An inadvertent experiment in humans has strengthened the
pathogenic role of GM1 as a triggering factor because patients who re-
ceived ganglioside injections for various maladies, developed AMAN
with GM1 antibodies [20]. Overall, IgG antibodies that react with GM1,
GD1a, GalNAc-GD1a and GM1b are found in 80% of patients with the ax-
onal formsofGBS (AMANandAMSAN); in contrast, in themost common
GBS subtype, the AIDP, anti-ganglioside antibodies are infrequent and
the antigenic targets remain still elusive. One ganglioside that clearly
correlates with a speciﬁc clinical syndrome is the GQ1b because IgG-
anti-GQ1b antibodies are speciﬁcally associated with the Miller-Fisher
variant and they are detected in more than 90% of these patients [1,2,8,
9]. In contrast, anti-GQ1b antibodies of the IgM class are found in some
patients with chronic IgM paraproteinemic polyneuropathies [1,2,19],
as discussed later. Anti-GQ1b IgG antibodies are also found in post-
infectious ophthalmoplegias and in GBS patients with ophthalmoplegia,
but not in GBS patients without ophthalmoplegia [1], probably because
GQ1b is present in the paranodal regions of oculomotor nerves III, IV,
and VI and the generated anti-GQ1b antibodies block impulse genera-
tion at the nodes of Ranvier resulting in conduction block. Many patients
with antibodies to GQ1b also have antibodies to GD1a [1,2,8,9]. TheFig. 1. A: Themain factors in the immunopathologyof autoimmuneperipheral neuropathies and
infections, such as Campylobacter jejuni, in a concept of molecular mimicry when glycoconjuga
zation of cross-reactive T cells and production of antibodies against myelin glycolipids. These a
phages lead to demyelination and conduction block. Macrophages act as effector cells and
upregulation of adhesion molecules (ICAM, VCAM, and MMP) on endothelial cells and transmi
body production. B. Targets of action of new biological agents as future immunotherapies in A
following: 1) T cell activation and intracellular signaling pathways, such as Alemtuzumab dire
an oral Janus Kinase inhibitor, that inhibits interleukin-2-dependent differentiation of Th17 he
rituximab, ocrelizumab, ofatumumab (Arzera) and obinutuzumab (Gazyva), against CD20 mole
drug Eculizumab, a monoclonal antibody against C5; 4) T cells and key Cytokines, such as Tocilizu
directed against IL17; and Ustekinumab, a human monoclonal antibody against the p40 subun
transmigration and Fingolimod, that traps lymphocytes in the lymphoid organs.reasons for different clinical syndromes in connection with speciﬁc
gangliosides remain unclear, but distribution, accessibility, density and
conformation of ganglioside epitopes at different sites may be critical
factors [1,2,17]. For example, there is more GM1 in ventral than in dorsal
roots, hence the predominantly motor neuropathy seen with GM1 anti-
bodies, and more GQ1b in the ocular motor nerves which explains the
ophthalmoplegia in Miller-Fisher syndrome.1.3.2.1. Triggering factors and molecular mimicry. Current evidence sug-
gests that antecedent infectionswith certain viral or bacterial infections
can break tolerance and trigger an autoimmune attack against myelin,
in a phenomenon of molecular mimicry, when glycoconjugate epitopes
are shared between bacterial and myelin proteins [1,2]. Two-thirds of
patients with GBS give a history of a ﬂu-like illness or acute dysenteric
episodes that precede the development of GBS by 1–3 weeks [1–3]. Vi-
ruses, such as Cytomegalovirus, Epstein–Barr virus (EBV), herpes, hepatitis
A and E, or HIV, and bacteria, such as Hemophilus inﬂuenza,Mycoplasma
pneumoniae and C. jejuni, are most commonly implicated. Among them,
infectionwith C. jejuni, which is themain culprit for certain GBS subsets,
has generated great interest because it provides the best example of
molecular mimicry [1–3]. High titers of IgG or IgM C. jejuni-speciﬁc an-
tibodies are seen in up to 30% of patientswith AMANand20%of patients
with Miller-Fisher syndrome and Campylobacter is isolated from the
stools early in acute GBS from 44% to 88% of the patients [1–3,8,9].
C. jejuni is a common cause of a diarrheal illness worldwide but it is a
certain serotype, the Penner D:19 serogroup, that differs from the
other enteritis-causing common serotypes because it contains the
genes for enzymes that synthesize sialic acid in the bacterial wall
mimicking gangliosides GM1, GD1a or GQ1b [1–3,8,9,22]. Bacterial
isolates from AMAN bear GM1-like or GD1a-like lipooligosaccharide,
while those from patients with Miller Fisher syndrome have
lipooligosaccharides mimicking GQ1b [2,3,8,9,22]. Further, injection of
lipo-oligosaccharides extracted from C. jejuni into rabbits induces an
acute neuropathy with GM1 antibodies, identical to AMAN, [1–3,22].
Accordingly, a classic example of molecular mimicry takes place when
infection by C. jejuni carrying GM1-like or GD1a-like lipooligosaccharide
induces antibodies to GM1 or anti-GD1a, which are expressed in motor
nerves, resulting clinically in AMAN [2,3,8,9]; in contrast, infection by
C. jejuni bearing GQ1b-mimicking lipooligosaccharide, generates anti-
GQ1b antibodies which, by binding to GQ1b expressed in oculomotor
nerves and muscle spindles, cause Miller Fisher syndrome [2,3,8,9].
Cross-reactivity between epitopes in the lipo-oligosaccharide of the
bacterial wall and the gangliosides on the peripheral nerve results in
sensitization of autoreactive T cells, production of complement-ﬁxing
anti-ganglioside antibodies and upregulation of cytokines and transmi-
grationmolecules on the endothelial cell wall facilitating the entrance of
more activated T cells to the endoneurial parenchyma [21]. The molec-
ular mimicry phenomenon as a triggering factor and the main immune
players involved in the pathogenesis of GBS are diagrammatically
depicted in Fig. 1A.
Molecular mimicry may be also involved with other bacteria.
Hemophilus inﬂuenzae, which is a triggering factor in 5% of GBS patients,
carries GM1 and GQ1b epitopes in its bacterial wall andmay cross-reactthe concept ofmolecularmimicry. The immune attack beginswhen tolerance is brokenby
te epitopes are shared between Campylobacter and peripheral myelin resulting in sensiti-
ntibodies by ﬁxing complement on the nerve or by binding to the Fc receptors on macro-
via co-stimulatory molecules, lead to clonal expansion of T-cells, release of cytokines,
gration of T-cells to myelin sheath. Cytokines IL-4, IL-6 enhance B-cell-activation and anti-
PN. Biological agents currently on the market for various autoimmune diseases target the
cted against the CD52 molecule; Daclizumab an IL-2 receptor antagonist; and Tofacitinib,
lper T cells; 2) B cells, such as Belimumab (Benlysta) against the B cell trophic factor Blys;
cules on B cells causing peripheral B cell depletion; 3) Complement, represented by the
mab, an IL6 receptor antagonist; Brodalumab and Ixekizumab, both monoclonal antibodies
it of IL12/1L-23; and 5) Cell adhesion and T cell migration, such as Natalizumab, that blocks
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which precedes GBS in 5% of cases, is another agent because it stimu-
lates antibodies against human carbohydrate antigens, including
galactocerebrocide, the main glycolipid antigen in the peripheral
nerve [1–3,21]. GBS triggered by CMV infection has been also associated
with the presence of IgM anti-GM2 antibodies [1,2]1.4. CIDP
1.4.1. Cellular factors
The role of autoimmune cells is becoming increasingly compelling in
the mechanism of CIDP. Although deﬁned as an “inﬂammatory
polyneuropathy”, the sural nerve biopsies from CIDP patients show
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are performed [1,2,10,20,22]. Thepredominant lymphoid cells consist of
macrophages, found scattered or in clusters around endoneurial vessels
[2,13–15,22,23]. Macrophages constitute the ﬁnal effector cells associat-
ed with demyelination because they express activationmarkers, proba-
bly induced by cytokines released by autoreactive T cells in situ or in the
circulation [2,10–16,24,25], penetrate the basement membrane of the
Schwann cell, displace the cytoplasm, split the myelin lamellae and
result in focal destruction of the myelin sheath (macrophage-mediated
demyelination). The macrophages, but also the Schwann cells, play a
role in local antigen presentation because they express the co-
stimulatory molecules B7-1, B7-2, while their counter-receptors CTLA-
4 and CD28 are expressed on the rare endoneurial CD4+ T cells [26,
27]. The role of B7-1/B7-2 is further supported by the development of
a spontaneous autoimmune polyneuropathy in a strain of non-obese di-
abetic mice deﬁcient in B7-2 co-stimulation that demonstrate clinical,
electrophysiological and immunopathological features similar to
human CIDP [28]. Preliminary data in a small series of patients, indicate
that the fewCD8+andCD4+T cells found in the nerve biopsies of CIDP
patients, have monoclonal or oligoclonal restrictions in their T-cell re-
ceptor repertoire that overlap with those found in the same patients'
peripheral blood lymphocytes, implying an antigen-driven T-cell
response against peripheral nerve antigens [29]. After successful treat-
ment with IVIg in a few of these patients, the oligoclonal expansions
of CD4+ and CD8+ populations appear reduced [30]; if these ﬁndings
are conﬁrmed inmore prospectively studied patients and correlatewith
the clinical response, changes in Vβ elements of the T cell receptors
might become interesting markers of CIDP responsiveness to IVIg [31].
Higher number of Th17-positive cells is also observed in the periph-
eral blood and CSF of CIDP patients with increased levels of circulating
interleukin-17 which augments the induction of co-stimulatory mole-
cules and enhances further the immune process [32]. The noted
dysfunction of immunoregulatory T cells may also play a role by affect-
ing the local inﬂammatory microenvironment and sustaining the ongo-
ing immune response [2,10,31–34]. Soluble adhesion molecules,
chemokines, cytokines and metalloproteinases are increased in the pa-
tients' sera, endothelial cells and CSF, facilitating T cell transmigration
across the blood–nerve barrier [34–38]. Gene array studies have con-
ﬁrmed the upregulation of genes for various inﬂammatory mediators
not only in the sural nerve biopsies [39] but also in the small nerveﬁbers
of the skin [40]. The skin biopsy is emerging as a powerful and accessible
tool to further explore themolecular events associated with the inﬂam-
matory process directly on the intradermal nerve ﬁbers andmonitor the
changes over time or after therapies.
1.4.2. Humoral factors
Humoral factors play a more fundamental role in CIDP owing to the
beneﬁcial effect of plasmapheresis that removes putative pathogenic
antibodies or other inﬂammatory mediators [1,2,10]. It is the fast re-
sponse of patients to plasmapheresis that implicates a circulating factor
– probably an antibody – responsible for demyelination and conduction
block. In contrast to GBS however, where ganglioside antibodies play a
causative role in the axonal and ataxic variants as discussed above, no
speciﬁc antibody has yet been identiﬁed as the causative factor in
CIDP, in spite of the compelling indirect evidence. The ﬁrst indication
that antibodies are involved in CIDP was the presence of complement-
ﬁxing IgG and IgM deposits on the patient's myelin sheath [41]; the
presence of a band, probably IgG, in their CSF provided further credence
[42]. Antibodies to glycolipids LM1, GM1, or GD1b were subsequently
detected in some patients, but less frequently detected than in GBS, al-
thoughmore frequently detected than in controls [43,44]. Passive trans-
fer experiments have then demonstrated that serum IgG can induce
conduction block in the rat nerves [45] implicating a 28 kDamyelin pro-
tein Po as a putative antigen, but only in 20% of the tested patients [46].
The recent observation that B cells from CIDP patients exhibit reduced
expression of FcγRIIB, an inhibitory receptor that prevents B cellsfrom entering the germinal centers to become IgG-positive plasma
cells [47], if conﬁrmed, may further support the role of B cells in the
disease.
In contrast to GBS where molecular mimicry with bacterial or viral
antigens triggers the disease in some patient subsets, there is no con-
vincing evidence that viral infections are antecedent events in CIDP. Of
interest is the observation that the incidence of CIDP is higher in pa-
tients with melanoma or after vaccination with melanoma lysates
[48]. Because several carbohydrate epitopes, such as GM3, GM2, GD3,
are shared between myelin and melanoma cells and the serum of one
such patient recognized GM2 epitopes on her own melanomatous
tumor, we have inferred that molecular mimicry may be a triggering
factor in such clinical settings [49]. Overall, the immunopathogenetic
scheme presented in Fig. 1A summarizing the proposed role of T cells,
cytokines, B cells and autoantibodies for GBS, is also relevant in CIDP.
1.4.2.1. Emerging target antigens in the nodal regions: an explanation for
conduction block and rapid recovery. In spite of the progress made in
the ﬁeld, the target antigen(s) in CIDP and in the commonest form of
GBS, the acute inﬂammatory demyelinating polyneuropathy (AIDP), re-
main still elusive. Recent studies however suggest that molecules not in
the compactmyelin aswehave been so far focused on, but ratherwithin
the nodal or paranodal regions and the Schwann cell/axonal interac-
tionsmay be probable candidate targets of the immune attack [2,50] be-
cause dysfunction in these regions can best explain the rapid changes in
clinical symptomatology seen in CIDP patients after treatment with
plasmapheresis or IVIg. Such a recovery is often noticeable within
days after treatment which cannot be explained on the basis of
remyelination but rather by the presence of a functional, “minute-to-
minute”, blockade induced by humoral factors againstmolecules associ-
ated with saltatory conduction at the nodes of Ranvier [2,10]. The same
is true for the worsening seen at the end of treatment effect, often pre-
dictable at 3–5 weeks, which cannot be due to an another predictable
demyelinating episode but rather due to reappearance of the conduc-
tion block across the nodes. Electron microscopy studies have now re-
vealed multiple alterations in the nodal and paranodal regions in the
Schwann cells of CIDP nerves compared to disease controls [51]. The
distribution of KCNQ2, a potassium channel subunit present in nodal re-
gions was found diminished in CIDP nerves, while paranodin, known as
CASPR, an axonal membrane glycoprotein highly enriched at the
paranodes, was more widespread in CIDP than in controls extending
along the axon in the internodes [51]. Analogous alterations were ob-
served in the demyelinated sciatic nerves of mice that exhibited in-
creased levels of paranodin/CASPR and increased density of ankyrin G
clusters [51]. Additionally, inmicewith EAN disruption of sodium chan-
nel clusters at the nodes of Ranvierwas associatedwith loss of adhesion
molecules gliomedin and neurofascin, that started before the loss of
sodiumchannels and the onset of paranodal demyelination, andwas ac-
companied by antibodies to gliomedin and neurofascin [52]. According-
ly, molecules in the nodal, paranodal or juxtaparanodal regions, as
depicted in Fig. 2, may be target antigens in human demyelinating
neuropathies that could best explain the conduction block. As depicted
in Fig. 2, someof the putative antigenic proteinswithin these regions in-
clude: at the node the neurofascin (NF186), gliomedin, sodium channels,
ankyrin G or spectrin; at the paranode the neurofascin 155, contactin/
Caspr 1 and connexins Cx31.3, Cx3232, Cx31.3, or 29; and at the
juxtaparanode the Transient Axonal Glycoprotein-1 (TAG-1)/CASPR 2
and potassium channels [52,53]. Immune responses against such mole-
culesmay change the ﬁne structure at the nodes and induce conduction
failure that would best explain the rapid recovery seen after therapy [2,
50].
A number of laboratories including ours, are actively searching for
antibodies against such targets. In one study, 43% of patients with GBS
and 30% of patients with CIDP showed IgG ﬁxation at the nodes of
Ranvier in an in vitro system; in eight of these patients IgG antibodies
recognized the native extracellular domain of neurofascin NF186,
Fig. 2. Proteins in the nodal, paranodal and juxtaparanodal regions of myelinated ﬁbers as target antigens in acquired demyelinating neuropathies with conduction block. Contactin 1, Na
+ channel, Ankyrin G, and Neurofascin 186 are the most common putative antigens in the nodal region; Neurofascin 155, CASPR 1/contactin 1 in the paranodal region; and contactin 2/
CASPR2 and K+ channel in the juxtaparanodal region. Additional ones (see text) include gliomedin, connexin, NCAM, cadherin and others. Part of theﬁgurewas adapted from Susuki [53]
with permission.
663M.C. Dalakas / Biochimica et Biophysica Acta 1852 (2015) 658–666gliomedin, or contactin [54]. In three other studies, high titer antibodies
to neurofascin have been observed in some patientswith CIDP and AIDP
but not in controls [55–57]. Although these antibodies were detected in
a small number of patients, there is evidence that they may be patho-
genic [57]. In another series, 4 of 46 (8.6%) CIDP patients reacted with
hippocampal neurons and paranodal structures on teased nerves,
while three of them (6.5%) had antibodies to contactin-1 and one to
contactin-associated protein 1 (CASPR 1) [58]. Of interest, the CASPR-
positive patients had poor response to IVIg, more axonal involvement
and aggressive course. The same group has also found in 4 other CIDP
patients who had predominant distal weakness, poor response to IVIg
and a disabling tremor, IgG4 antibodies to neurofascin-155; these pa-
tients' serum immunoreacted with paranodes in teased-nerve ﬁbers
and with the neuropil of rat cerebellum, brain, and brainstem [59]. It
is likely that different antibodies at the nodal regionmay identify differ-
ent CIDP phenotypes. Polymorphisms in the TAG-1molecule have been
also noted in CIDP patients and it was suggested that TAG-1 may be a
target antigen [60].We have tested 15 CIDP patients for TAG-1 antibod-
ies using a cell-based assay in our laboratory, but we did not identify
any positive sera [61]. Further, testing for reactivity to CASPR 2, which
is localized in the juxtaparanodal region (Fig. 2), using a sensitive cell-
based assay also failed to detect antibodies [62]. A more recent screen
of 45 CIDP patients for contactin-2/TAG1, Connexins Cx31.3 and Cx32,
as well as CASPR 2 was still disappointing except for one patient that
recognized a heretofore-unidentiﬁed antigen at the node in a teased
nerve ﬁber preparation [63]. In spite of the very small number of posi-
tive sera, the plethora of proteins in the nodal regions, open the way
to explore other candidate target antigens, especially against proteins
with an extracellular domain, in an effort to identify distinct patient
subsets.1.5. IgM-MGUS neuropathy with anti-mag or SGPG antibodies
Among patients with paraproteinemias, the best characterized
antibody-mediated neuropathy is the one associated with IgM
monoclonal gammopathy. The sera from approximately 50% of these
patients react with myelin-associated glycoprotein (MAG), a 100-kDa
glycoprotein of the central and peripheral nerve myelin, as well as
other glycoproteins or glycolipids that share antigenic determinants
with MAG [1,2,64–68]. The antigenic determinant of MAG resides in
the carbohydrate component of the molecule because after deglycosyl-
ation of MAG the IgM reactivity is lost [67]. Most importantly, the anti-
MAG IgMparaproteins always reactwith an acidic glycolipid in the gan-
glioside fraction of the human peripheral nerve that we had identiﬁed
as a sulfoglucuronyl glycosphingolipid (SGPG) [68]. SGPG is more rele-
vant in the pathogenesis of the neuropathy because, in contrast to MAG
which is mostly present in the CNSmyelin, SGPG is found exclusively in
the peripheral nerve. In addition, animals we immunized with SGPG
develop an ataxic neuropathy similar to the one seen in IgM-MGUS
patients. More than half of the IgM paraproteins in patients with neu-
ropathy recognize MAG and SGPG, while 75% of the rest recognize
other ganglioside antigens, most commonly those that contain either
a disialosyl moiety, such as GD1b, GQ1b, GT1b, the GalNac-GM1b and
GalNAc-GD1a, or two gangliosides that share epitopes with GM2, or a
combination of GM2 and GM1, GM1 and GD1b [1,19,69,70]. Acidic gly-
colipids are therefore, the most common antigenic epitopes in IgM-
MGUS patients [1,19,69,70].
Because anti-MAG-reacting sera always recognize the SGPG glyco-
lipid, the assay is often performed using SGPG as antigen instead of pu-
riﬁed human MAG [1]. It should be noted however that IgM binds to
MAG 10–100 times more strongly than to SGPG, and checking for
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MAG antibodies [1,2].
There is strong evidence that MAG/SGPG antibodies are causatively
related to the neuropathy because: a) IgM and complement are depos-
ited on the myelinated ﬁbers in the patient's sural nerve biopsies sug-
gesting that activated complement is ﬁxed in situ by the antibodies
[71]; b) the patients' IgM recognizes the neural cell adhesion molecule
NCAM and co-localizes withMAG on the areas of the split myelin impli-
cating a myelin disadhesion process induced by the circulating anti-
MAG IgM [72]; c) in skin biopsies from the patients, there is deposition
of IgM, complement and MAG on the intradermal myelinated ﬁbers
with a concurrent loss of nerve ﬁbers suggesting IgM-induced
ﬁber loss [72]; d) intraneural injections of the patients' serum supple-
mented with fresh complement into peripheral nerve of cats results in
a complement-dependent demyelination with conduction block, 2–9
days after the injection; the injected serum also caused splitting of the
outer layer of the myelin sheath resembling the human pathology
[73]; d) systemic transfusion of anti-MAG IgM paraproteins causes seg-
mental demyelination in chickens with deposition of IgM to the outer
layers of the myelin sheath and splitting of the myelin lamellae similar
to the one seen in the patients' nerves [74]; and e) immunization of
cats with SGPG causes sensory ataxia, as seen in patients with anti-
MAG neuropathy, and an inﬂammatory ganglionopathy with dorsal
root involvement consistent with the clinical signs of sensory ataxia
[75].
1.5.1. Current therapies and emerging disease biomarkers
The autoimmune neuropathies are clinically important because they
respond to treatment with various immunomodulating or chemothera-
peutic agents. Randomized clinical trials have shown that intravenous
immunoglobulin (IVIg) and plasma exchange are equally effective in
GBS [76], although somepatients do not adequately respond for reasons
that remain still unclear. In CIDP, corticosteroids, IVIg and plasma ex-
change exert a short- or long-term meaningful clinical improvement
in the majority of the patients, but maintenance therapy is required
[2,10,77,78]. In MMN, the only effective therapy is IVIg but remains
curious why this neuropathy does not respond to any other immuno-
therapy and worsens with corticosteroids. Anti-MAG neuropathy is re-
fractory to available therapies [1,79], but a small number of patients
respond verywell to Rituximab [80]. Immunosuppressants, such as aza-
thioprine, cyclosporine, mycophenolate, or cyclophosphamide are vari-
ably used as steroid- or IVIg-sparing agents in all APN [80], but their
efﬁcacy is overall disappointing. Controlled trials with β-interferon
and methotrexate were ineffective in CIDP [81–83]. Because some
CIDP patients respond only to steroids, while others with pure motor
disease worsen with steroids and still others respond only to plasma-
pheresis or IVIg [10,84], biomarkers predicting response to therapies
from the outset are needed [84].
Pharmacokinetic studies in 174 GBS patients treated with IVIg have
shown that patients with a lower increase in serum IgG (DeltaIgG) re-
covered more slowly and fewer of them reached the ability to walk un-
aided at six months, concluding that a low DeltaIgG was independently
associatedwith poor outcome [85]. If conﬁrmed, thiswould suggest that
patients might beneﬁt from a higher dosage or from a second IVIg infu-
sion early in the disease course. Serum IgG levels after IVIg infusions do
not seem to play a role in predicting responsiveness of CIDP to IVIg. Two
potential biomarkers, the TAG-1 (Transient Axonal Glycoprotein-1), an
adhesion molecule involved in axonal maintenance, and the expression
of inhibitory FcγRIIB receptors on B cells [59,47], seem promising in
conferring responsiveness to IVIg. Single nucleotide polymorphisms
and haplotype studies in 100 Japanese patients, revealed an association
between IVIG responsiveness and TAG-1 polymorphism [59], suggest-
ing that response to IVIg may be even genetically determined. The in-
hibitory FcγRIIB receptors on B cells transduce inhibitory signals and
prevent their transformation into IgG-producing plasma cells [47]. Pa-
tients with CIDP were found to have lower FcγRIIB on naive B cells,but after IVIg the FcγRIIB protein expression was upregulated; whether
such an upregulatory effect of IVIg on FcγRIIB of B cells predicts respon-
siveness to IVIg, remains to be proven [84].
1.5.2. Emerging biological agents as new targeted therapies
There is a need for more effective and speciﬁc therapies for all APN
because: a) a number of patients with GBS or CIDP do not adequately
respond to the available therapies and left with signiﬁcant disability;
b) there is a need for steroid and IVIg-sparing effect in CIDP to diminish
the long-term steroid-related side effects and reduce the high cost of
monthly IVIg maintenance; c) a number of patients with MMN do not
adequately respond to IVIg or the efﬁcacy wanes with time; and d)
very few patients with anti-MAG neuropathy respond only to Rituxi-
mab [80,86]. Emerging therapeutic agents in the form of monoclonal
antibodies or fusion proteins offer target-speciﬁc therapy and are cur-
rently used in other autoimmune disorders, as discussed [87,88].
These agents may be of value as future therapies in all APN because
they target key molecules involved in immunopathology of the disease
from the early T and B cell activation to the ﬁnal induction of cytotoxic-
ity including cytokines, complement, and adhesion or transmigration
molecules, as depicted in Fig. 1B [2,10,87,88]. As emphasized [2], these
drugs may be considered as future therapeutic options, provided that
they are tested in control trials and the rare but potentially catastrophic
side effects are being monitored. The new biological agents target the
following.
1.5.2.1. T cell intracellular signaling pathways. This group includes: a)
Alemtuzumab, a monoclonal antibody against the CD52 transduction
molecule, that causes long-lasting lymphocyte depletion. Alemtuzumab
has been effective in multiple sclerosis and seems promising in CIDP [2,
10,9,87,88] where a controlled trial is ready to begin; b) Daclizumab, a
monoclonal antibody against CD25 (IL-2 receptor antagonist) that in-
hibits T cell proliferation. The drug is well tolerated, has been approved
for leukemia, and is very promising in patientswithMultiple Sclerosis in
two phase III clinical trials; c) Tofacitinib, an oral Janus Kinase inhibitor,
that inhibits interleukin-2-dependent differentiation of type 2 and type
17 helper T cells and attenuates signaling by proinﬂammatory cyto-
kines, such as interleukin-6 and interferon-γ. Blockade of Janus kinases
suppresses both T and B cells and maintains Regulatory T-cell function.
The drug has been effective in ulcerative colitis and rheumatoid arthritis
[87,88].
1.5.2.2. B cells and B cell trophic factors. They include: i) Belimumab
(Benlysta), a humanmonoclonal antibody against B-lymphocyte stimu-
lator (BLyS) that has been approved for lupus; ii) rituximab, a chimeric
monoclonal antibody directed against CD20, a membrane-associated
phosphoprotein present on B cells, causes peripheral B cell depletion
[87–90]. Rituximab is given in two, 1 g each infusions, 15 days apart in-
travenously or in 4 weekly infusions each at 375 mg/m2; up to 50% of
the treated patients with CIDP seem to improve after 2–12 months
[91] but controlled studies are needed. Rituximab also helps a number
of patientswith anti-MAGneuropathy, 6–8 months after one 2 gram in-
fusion [80,86]; iii) ocrelizumab, the humanized version of rituximab; iv)
ofatumumab (Arzera) that targets different CD20 epitopes and can be
given subcutaneously; and v) Obinutuzumab (Gazyva), another mono-
clonal antibody against CD20 that causes more profound B cell deple-
tion and has been approved for chronic lymphocytic leukemia.
1.5.2.3. Complement. Eculizumab, a monoclonal antibody against C5 in-
tercepts the terminal formation of membranolytic attack complex
(MAC) and blocks the generation of proinﬂammatory molecules [92,
93]. The agent, approved for paroxysmal hemoglobinuria, is of interest
in CIDP and GBS where complement is activated and deposited on the
nerves. The drug was effective in an EANmodel, showed some promise
in a small uncontrolled trial in MMN patients, and was effective in a
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Eculizumab is ready to begin in GBS.
1.5.2.4. Cytokines and cytokine receptors. Themost relevant agents in this
group include: i) Tocilizumab, an IL6 receptor antagonist,which is prom-
ising in SLE and is relevant to APN because IL6 affects the induction of
Tregs to pathogenic Th1 cells; ii) Brodalumab and Ixekizumab, both
monoclonal antibodies directed against IL17, which have been recently
shown to be effective in psoriasis; and iii) Ustekinumab, a humanmono-
clonal antibody against the p40 subunit of IL12/1L-23, which has shown
effectiveness in psoriatic arthritis and has been approved for plaque
psoriasis [88].
1.5.2.5. Cell adhesion and T cell migration. The main drug in this category
is Natalizumab, approved for multiple sclerosis and Crohn's disease,
which prevents adhesion and transmigration of both T and B cells by
binding to α4β1 integrin (VLA4) on leucocytes. Although ineffective in
one CIDP case [94], it is a reasonable drug to consider for experimental
trials in APN. Fingolimod, an oral anti-T-cell-migration agent that traps
lymphocytes in the lymphoid organs, has been approved for multiple
sclerosis and is currently tested in an ongoing trial in CIDP.
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